{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"4.2","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From study entry to the first of either disease progression or death from any cause, assessed up to 2 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}